Science to Practice: Molecular-targeted Drug Delivery in Combination with Radiofrequency Ablation of Liver Cancer: A Magic Bullet?

Radiology. 2017 Nov;285(2):333-335. doi: 10.1148/radiol.2017171527.

Abstract

In an effort to improve the technical success rates and clinical outcomes of radiofrequency (RF) ablation, Yan et al validated the use of a tumor-penetrating peptide and thermosensitive doxorubicin (DOX)-loaded nanoparticles in combination with RF ablation in a hepatocellular carcinoma mouse model. By achieving higher chemotherapeutic drug concentrations in target lesions, fewer toxic effects, and improved survival end points in an animal tumor model, the authors conclude that superior tumor treatment with RF ablation is possible when combined with molecular-targeted drug delivery systems.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / therapeutic use
  • Catheter Ablation / methods*
  • Doxorubicin / chemistry
  • Doxorubicin / therapeutic use
  • Drug Carriers* / chemistry
  • Drug Carriers* / therapeutic use
  • Liver Neoplasms, Experimental* / diagnostic imaging
  • Liver Neoplasms, Experimental* / drug therapy
  • Mice
  • Molecular Imaging / methods*
  • Nanoparticles / chemistry
  • Nanoparticles / therapeutic use
  • Peptides / chemistry
  • Peptides / therapeutic use
  • Theranostic Nanomedicine

Substances

  • Antineoplastic Agents
  • Drug Carriers
  • Peptides
  • Doxorubicin